Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D7OZC3
|
|||
Drug Name |
Tolebrutinib
|
|||
Synonyms |
Tolebrutinib; 1971920-73-6; PRN2246; SAR442168; c]pyridin-2-one; Tolebrutinib [INN]; Tolebrutinib [USAN]; PRN-2246; 8CZ82ZYY9X; SAR-442168; (R)-1-(1-Acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1H-imidazo[4,5-c]pyridin-2(3H)-one; 4-amino-3-(4-phenoxyphenyl)-1-[(3R)-1-prop-2-enoylpiperidin-3-yl]imidazo[4,5-c]pyridin-2-one; 4-amino-3-(4-phenoxyphenyl)-1-[(3R)-1-(prop-2-; enoyl)piperidin-3-yl]-1,3-dihydro-2H-imidazo[4,5-; 2H-Imidazo(4,5-C)pyridin-2-one, 4-amino-1,3-dihydro-1-((3R)-1-(1-oxo-2-propen-1-yl)-3-piperidinyl)-3-(4-phenoxyphenyl)-; 4-Amino-1,3-dihydro-1-((3R)-1-(1-oxo-2-propen-1-yl)-3-piperidinyl)-3-(4-phenoxyphenyl)-2H-imidazo(4,5-C)pyridin-2-one; Tolebrutinib [USAN:INN]; UNII-8CZ82ZYY9X; TOLEBRUTINIB [WHO-DD]; CHEMBL4650323; SCHEMBL18285621; GTPL10625; BTK'168; EX-A4699; BDBM50557487; WHO 11268; AKOS040759681; example 3 [WO2016196840A1]; SAR442168; PRN2246; MS-28304; HY-109192; CS-0119132; EN300-6498433; 4-amino-3-(4-phenoxyphenyl)-1-[(3R)-1-(prop-2-enoyl)piperidin-3-yl]-1H,2H,3H-imidazo[4,5-c]pyridin-2-one
Click to Show/Hide
|
|||
Drug Type |
Small molecule
|
|||
Indication | Multiple sclerosis [ICD-11: 8A40] | Phase 3 | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C26H25N5O3
|
|||
Canonical SMILES |
C=CC(=O)N1CCCC(C1)N2C3=C(C(=NC=C3)N)N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5
|
|||
InChI |
InChI=1S/C26H25N5O3/c1-2-23(32)29-16-6-7-19(17-29)30-22-14-15-28-25(27)24(22)31(26(30)33)18-10-12-21(13-11-18)34-20-8-4-3-5-9-20/h2-5,8-15,19H,1,6-7,16-17H2,(H2,27,28)/t19-/m1/s1
|
|||
InChIKey |
KOEUOFPEZFUWRF-LJQANCHMSA-N
|
|||
PubChem Compound ID |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT04411641) A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis. U.S.National Institutes of Health. | |||
REF 2 | Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021 Sep;20(9):729-738. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.